PharmaShots | Incisive News in 3 Shots

Subscribe Now

Triple Regimen

Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

August 25, 2020

Eli Lilly and Boehringer Ingelheim's Triple Regimen Receive the US FDA's Approval for Type 2 Diabetes

Eli Lilly and Boehringer Ingelheim's Triple Regimen Receive the US FDA's Approval for Type 2 Diabetes

January 28, 2020

Celgene's Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada's Approval for Multiple Myeloma

Celgene's Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada's Approval for Multiple Myeloma

July 11, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us